This statement reviews sex-specific data on the safety and efficacy of contemporary percutaneous coronary intervention and adjunctive pharmacotherapy in women.
More than 1.2 million percutaneous coronary interventions are performed annually in the United States, with only an estimated 33% performed in women, despite the established benefits of percutaneous coronary intervention and adjunctive pharmacotherapy in reducing fatal and nonfatal ischemic complications in acute myocardial infarction and high-risk acute coronary syndromes. This statement reviews sex-specific data on the safety and efficacy of contemporary interventional therapies in women.
Lansky et al. (Wed,) conducted a review in Acute myocardial infarction and high-risk acute coronary syndromes. Percutaneous coronary intervention and adjunctive pharmacotherapy was evaluated. This statement reviews sex-specific data on the safety and efficacy of contemporary percutaneous coronary intervention and adjunctive pharmacotherapy in women.